- $578.75m
- $1.70bn
- $155.16m
- 49
- 57
- 20
- 37
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 37.4 | 45.3 | 71.8 | 101 | 155 |
Cost of Revenue | |||||
Gross Profit | 30.6 | 35.6 | 57.8 | 83.6 | 126 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 24.8 | 32.8 | 41 | 85.4 | 138 |
Operating Profit | 12.6 | 12.5 | 30.8 | 15.8 | 17 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -7.38 | -1.8 | 13.3 | 53.2 | -26.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -8.56 | -1.89 | 13 | 52.2 | -26 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -4.37 | 6.79 | 5.91 | 55.4 | -9.36 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -6.12 | -11 | 5.82 | 55 | -9.36 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.036 | -0.067 | -0.014 | 0.377 | -0.037 |
Dividends per Share |